Omega Funds Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 17

Professionals

  • Investments
  • 193

  • Portfolio
  • 48

  • Exits
  • 123

Exits

Omega Funds General Information

Company Description

Founded in 2004, Omega Funds is a venture capital firm based in Boston, Massachusetts. The firm seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.

Business Details

Year Founded
2004
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Corporate Office
  • 888 Boylston Street
  • Suite 1111
  • Boston, MA 02199
  • United States
+1 (617) 000-0000

Omega Funds Investments (193)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
ARTBIO 07-Dec-2023 Early Stage VC 0000 Biotechnology Pre-Clinical Trials 000000000 0000000
Bicara Therapeutics 06-Dec-2023 00000 00000 00000 Drug Discovery Clinical Trials - Phase 2
EyeBio 14-Nov-2023 00000 00000 00000 Drug Delivery Generating Revenue 0000000 00000000
Bicara Therapeutics 08-Sep-2023 00000 00000 00000 Drug Discovery Clinical Trials - Phase 2
Beta Bionics 30-Aug-2023 00000 00000 00000 Monitoring Equipment Generating Revenue
ARTBIO 21-Jun-2023 0000 00000 0000 Biotechnology Pre-Clinical Trials 000000 00000000000 00.0
Upstream Bio 06-Jun-2023 00000 00000 00000 Biotechnology Clinical Trials - General 0000000 00000000
enGene 17-May-2023 0000 00000 Biotechnology Clinical Trials - General
Chroma Medicine 08-Feb-2023 Early Stage VC 00000 Drug Discovery Startup
SoniVie 09-Jan-2023 Later Stage VC 0000 Diagnostic Equipment Generating Revenue 0000000 00000 00.0
You’re viewing 10 of 193 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Omega Funds Exits (123)

Company Name Exit Date Exit Type Exit Size
Alpine Immune Sciences 06-Nov-2023 Public Investment 2nd Offering 00000
Lexeo Therapeutics 03-Nov-2023 000 00000
Paratek Pharmaceuticals 21-Sep-2023 0000000000 00000
Epigenomics 24-Jul-2023 000000000000000000 000.00
Imago BioSciences 11-Jan-2023 000000000000000000 00.000
Replimune 12-Dec-2022 000000 0000000000 00000
Oxagen 04-Nov-2022 0000000000: 000000
abiliti 02-Sep-2022 000 00 00000000
Senti Bio 08-Jun-2022 Reverse Merger 00000
Amunix Pharmaceuticals 08-Feb-2022 Merger/Acquisition 00.000
You’re viewing 10 of 123 exits. Get the full list »

Omega Funds Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Omega Funds Management, Team & Partners (33)

Name Title Deals Funds Boards Office
Alexandra Pearsall Chief Financial Officer Boston, MA
Otello Stampacchia Ph.D Founder and Managing Director 00 0 00 Boston, MA
Anne-Mari Paster Managing Director 0 Boston, MA
Claudio Nessi Ph.D Managing Director 00 0 0 Boston, MA
Francesco Draetta Managing Director 0 0 Boston, MA
You’re viewing 5 of 33 team members. Get the full list »

Omega Funds Co-Investors (207)

Name With Exits Lead Partner Series Industry
Citadel Enterprise Americas 7 0 Series chart Industry bar
Perceptive Advisors 0 0 Series chart Industry bar
OrbiMed 0 0 0 Series chart Industry bar
T. Rowe Price 0 0 0 Series chart Industry bar
The Invus Group 0 0 Series chart Industry bar
You’re viewing 5 of 207 co-investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »